vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $247.1M, roughly 1.0× ANI PHARMACEUTICALS INC). WESBANCO INC runs the higher net margin — 34.5% vs 11.1%, a 23.3% gap on every dollar of revenue. Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 31.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
ANIP vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $257.2M |
| Net Profit | $27.5M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 34.5% |
| Revenue YoY | 29.6% | — |
| Net Profit YoY | 367.5% | 54.4% |
| EPS (diluted) | $1.14 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $247.1M | $265.6M | ||
| Q3 25 | $227.8M | $261.6M | ||
| Q2 25 | $211.4M | $260.7M | ||
| Q1 25 | $197.1M | $193.2M | ||
| Q4 24 | $190.6M | $162.9M | ||
| Q3 24 | $148.3M | $150.8M | ||
| Q2 24 | $138.0M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $27.5M | $91.1M | ||
| Q3 25 | $26.6M | $83.6M | ||
| Q2 25 | $8.5M | $57.4M | ||
| Q1 25 | $15.7M | $-9.0M | ||
| Q4 24 | $-10.3M | $49.6M | ||
| Q3 24 | $-24.2M | $37.3M | ||
| Q2 24 | $-2.3M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 43.2% | ||
| Q3 25 | 15.9% | 39.5% | ||
| Q2 25 | 6.6% | 27.2% | ||
| Q1 25 | 13.3% | -5.0% | ||
| Q4 24 | -2.3% | 38.0% | ||
| Q3 24 | -13.8% | 29.7% | ||
| Q2 24 | 3.7% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 11.1% | 34.3% | ||
| Q3 25 | 11.7% | 31.9% | ||
| Q2 25 | 4.0% | 22.0% | ||
| Q1 25 | 8.0% | -4.7% | ||
| Q4 24 | -5.4% | 30.5% | ||
| Q3 24 | -16.3% | 24.7% | ||
| Q2 24 | -1.7% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $1.14 | $0.97 | ||
| Q3 25 | $1.13 | $0.84 | ||
| Q2 25 | $0.36 | $0.57 | ||
| Q1 25 | $0.69 | $-0.15 | ||
| Q4 24 | $-0.45 | $0.72 | ||
| Q3 24 | $-1.27 | $0.54 | ||
| Q2 24 | $-0.14 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $4.1B |
| Total Assets | $1.4B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | $956.1M | ||
| Q3 25 | $262.6M | $1.0B | ||
| Q2 25 | $217.8M | $1.2B | ||
| Q1 25 | $149.8M | $1.1B | ||
| Q4 24 | $144.9M | $568.1M | ||
| Q3 24 | $145.0M | $620.9M | ||
| Q2 24 | $240.1M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $540.7M | $4.0B | ||
| Q3 25 | $505.8M | $4.1B | ||
| Q2 25 | $436.8M | $3.8B | ||
| Q1 25 | $418.6M | $3.8B | ||
| Q4 24 | $403.7M | $2.8B | ||
| Q3 24 | $405.9M | $2.8B | ||
| Q2 24 | $455.8M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.4B | $27.7B | ||
| Q3 25 | $1.4B | $27.5B | ||
| Q2 25 | $1.3B | $27.6B | ||
| Q1 25 | $1.3B | $27.4B | ||
| Q4 24 | $1.3B | $18.7B | ||
| Q3 24 | $1.3B | $18.5B | ||
| Q2 24 | $920.8M | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $290.4M | ||
| Q3 25 | $44.1M | $116.9M | ||
| Q2 25 | $75.8M | $105.0M | ||
| Q1 25 | $35.0M | $-26.4M | ||
| Q4 24 | $15.9M | $211.0M | ||
| Q3 24 | $12.5M | $60.7M | ||
| Q2 24 | $17.4M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $280.0M | ||
| Q3 25 | $38.0M | $114.9M | ||
| Q2 25 | $71.8M | $98.3M | ||
| Q1 25 | $32.5M | $-30.7M | ||
| Q4 24 | $13.5M | $200.7M | ||
| Q3 24 | $7.7M | $56.9M | ||
| Q2 24 | $13.0M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 105.4% | ||
| Q3 25 | 16.7% | 43.9% | ||
| Q2 25 | 34.0% | 37.7% | ||
| Q1 25 | 16.5% | -15.9% | ||
| Q4 24 | 7.1% | 123.2% | ||
| Q3 24 | 5.2% | 37.7% | ||
| Q2 24 | 9.4% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 3.9% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 6.3% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.2% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.19× | ||
| Q3 25 | 1.66× | 1.40× | ||
| Q2 25 | 8.87× | 1.83× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
